Do Traders Think Applied Therapeutics Inc (APLT) Can Keep Climbing Monday?

Applied Therapeutics Inc (APLT) stock has gained 12.42% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator.

Applied Therapeutics Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on APLT!

See Full APLT Report

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With APLT Stock Today?

Applied Therapeutics Inc (APLT) stock is trading at $6.70 as of 9:40 AM on Monday, Mar 25, a decline of -$0.05, or -0.73% from the previous closing price of $6.75. The stock has traded between $6.49 and $6.85 so far today. Volume today is low. So far 131 shares have traded compared to average volume of 2,821,475 shares. To see InvestorsObserver's Sentiment Score for Applied Therapeutics Inc click here.

More About Applied Therapeutics Inc

Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The lead product candidate of the company is AT-001, which is a novel ARI with broad systemic exposure and peripheral nerve permeability, developed for the treatment of diabetic cardiomyopathy, or DbCM, a fatal fibrosis of the heart. Click Here to get the full Stock Report for Applied Therapeutics Inc stock.